Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 47

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 47
---
 December 31, 202346,481 — $46 $— $976,633 $(106,796)$247 $870,130 Vested restricted stock units448 — 1 — — — — 1 Common stock withheld for employee withholding tax liabilities on vested restricted stock units— — — — (414)— — (414)Common stock issued under employee stockpurchase plan56 — — — 1,364 — — 1,364 Stock-based compensation— — — — 38,905 — — 38,905 Purchase of treasury stock, inclusive of excise tax— (837)— (25,121)— — — (25,121)Purchase of capped call transaction, net of tax— — — — (20,112)— — (20,112)Other comprehensive income (Note 11)— — — — — — 431 431 Net loss— — — — — (115,601)— (115,601)Balance at September 30, 202446,985 (837)$47 $(25,121)$996,376 $(222,397)$678 $749,583 

See accompanying notes to condensed consolidated financial statements.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  6

PACIRA BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 (In thousands)

(Unaudited)

Nine Months EndedSeptember 30, 20252024Operating activities:  Net income (loss)$5,397 $(115,601)Adjustments to reconcile net income (loss) to net cash provided by operating activities:  Goodwill impairment— 163,243 Indefinite-lived intangible asset impairment25,866 — Investment impairment11,000 — Deferred taxes10,221 17,113 Depreciation of fixed assets and amortization of intangible assets69,681 57,542 Amortization of debt issuance costs2,320 2,284 Amortization of debt discount101 70 Loss (gain) on early extinguishment of debt983 (7,518)Stock-based compensation44,003